Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19
Authors:
- Davey M. SmithDSDavey M. Smith
- Jonathan Z. LiJLJonathan Z. Li
- Carlee MoserCMCarlee Moser
- Judith S. CurrierJCJudith S. Currier
- Kara W. ChewKCKara W. Chew
- Michael D. HughesMHMichael D. Hughes
- ACTIV-2/A5401 Study TeamATACTIV-2/A5401 Study Team
- Eric DaarEDEric Daar
- David WohlDWDavid Wohl
- Joseph EronJEJoseph Eron
Open Access
- 27 October 2022
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (10) , e2238867
Abstract
Recurrence of symptoms after finishing treatment for COVID-19 with nirmatrelvir-ritonavir (Paxlovid) has become increasingly recognized.1-3 The biological underpinning of this phenomenon is unclear, and its etiology may be multifactorial, including rapid clearance of nirmatrelvir coupled with delayed immune responses or possible development of drug resistance.1-3 The contribution of treatment to symptom rebound needs to be differentiated from symptom rebound that might occur during the natural history of COVID-19. In this cohort study, we sought to determine how often COVID-19 symptoms recurred when the disease was untreated.Keywords
This publication has 6 references indexed in Scilit:
- Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir TreatmentNew England Journal of Medicine, 2022
- Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Nature Communications, 2022
- Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)Clinical Infectious Diseases, 2022
- Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir TreatmentClinical Infectious Diseases, 2022
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern AfricaNature, 2022
- Characteristics and Timing of Initial Virus Shedding in Severe Acute Respiratory Syndrome Coronavirus 2, Utah, USAEmerging Infectious Diseases, 2021